MGO One Seven LLC Has $2.70 Million Holdings in Novartis AG (NYSE:NVS)

MGO One Seven LLC grew its holdings in Novartis AG (NYSE:NVS - Free Report) by 12.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 27,710 shares of the company's stock after purchasing an additional 3,042 shares during the quarter. MGO One Seven LLC's holdings in Novartis were worth $2,696,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in NVS. Human Investing LLC bought a new position in Novartis in the 4th quarter worth approximately $25,000. Union Bancaire Privee UBP SA acquired a new stake in shares of Novartis in the fourth quarter worth $27,000. Kestra Investment Management LLC bought a new position in Novartis during the fourth quarter worth $47,000. Clearstead Trust LLC bought a new stake in Novartis in the 4th quarter valued at $51,000. Finally, Brooklyn Investment Group bought a new position in shares of Novartis during the 4th quarter worth about $55,000. 13.12% of the stock is currently owned by institutional investors.

Novartis Price Performance

Shares of NVS traded up $1.06 during trading hours on Friday, hitting $112.23. The stock had a trading volume of 2,213,607 shares, compared to its average volume of 1,544,101. The stock has a market capitalization of $237.08 billion, a price-to-earnings ratio of 19.09, a P/E/G ratio of 1.70 and a beta of 0.56. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. The company's fifty day moving average is $109.68 and its two-hundred day moving average is $106.16. Novartis AG has a 52 week low of $96.06 and a 52 week high of $120.92.

Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. On average, analysts anticipate that Novartis AG will post 8.45 EPS for the current year.

Novartis Dividend Announcement

The firm also recently declared a dividend, which was paid on Wednesday, March 12th. Investors of record on Wednesday, March 12th were issued a $3.8695 dividend. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis's dividend payout ratio is 44.05%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a "hold" rating to a "buy" rating in a research note on Tuesday, February 4th. Morgan Stanley began coverage on Novartis in a report on Wednesday, February 12th. They set an "underweight" rating on the stock. StockNews.com upgraded Novartis from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 8th. BNP Paribas upgraded shares of Novartis to a "strong-buy" rating in a research note on Tuesday, April 15th. Finally, UBS Group restated a "neutral" rating on shares of Novartis in a research note on Thursday, February 13th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.